Allergan announces Q2 operating result update

Allergan has announced a positive set of operating results for the second quarter of 2012.

The company's findings relate to the three months to June 30th 2012 and highlight a 4.8 percent net sales increase for the quarter to $1,467.4 million (941.2 million pounds) in comparison to the same period last year.

Meanwhile, the firm reported diluted earnings per share attributable to stockholders of $0.96 in Q2 2012- up from $0.76.

"In the second quarter, Allergan continued to deliver strong earnings growth in spite of the strong US dollar relative to virtually all major currencies," said David Pyott, Allergan's chairman of the board, president and chief executive officer.

He added that the firm continues to focus strongly on efficiency improvements as it looks to invest strongly in further R&D efforts over the coming months.

The company specialises in the provision of technology and products for health professionals operating in the eye care, neurosciences, medical dermatology and urologics sectors.